The present invention provides FAHD1 for use in a method for the treatment or prevention of aberrations of the energy metabolism of the nervous system, pancreas, kidney, liver, muscles or adipose tissue. Further, a method of decarboxylating an organic compound is provided, which uses FAHD1 to decarboxylate the organic compound. Additionally, a method and a kit for identifying inhibitors of FAHD1 are provided.

Provided is a method for screening a compound that can specifically suppress the formation of caveolae of cancer cells and can inhibit the activity of various RTKs using a single compound all at once. A method for screening a compound specifically suppressing the formation of caveolae of cancer cells wherein the screening method includes a step for bringing a test compound into contact with a system capable of detecting suppression of the binding of Cavin-1 and CAV1 and a step for selecting a compound having activity to suppress the binding of Cavin-1 and CAV1.

Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of modulators of inflammation.

Provided by the invention are methods for identifying therapeutic agents for treating multiple myeloma or another hematological malignancy, as well as methods for determining the prognosis of a patient with multiple myeloma or another hematological malignancy. The methods are based in part on the inventors' discovery that an extracellular form of cyclophilin A binds to CD147 expressed on multiple myeloma cells.

The present disclosure is directed to methods of screening a compound for modulating activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of fibroblast growth factor-inducible 14 (Fn14). The present disclosure also provides heterocyclic compounds and pharmaceutically acceptable salts thereof and methods for the prevention, treatment, and amelioration of cell proliferative disorders with these compounds.

Cyclic-GMP-AMP (cGAMP), including 2′,3′-cGAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.

The invention provides kinase substrates and methods comprising their use.

The present disclosure provides a protein complex, including a three-dimensional structure of the protein complex, that plays a role in regulation of body weight. In addition, the protein complex and components thereof, including three-dimensional structures thereof, find use in identifying agents that can be used to control body weight.

The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.